https://www.selleckchem.com/pr....oducts/asunaprevir.h
Application of advanced molecular pathology in rare tumours is hindered by low sample numbers, access to specialised expertise/technologies and tissue/assay QC and rapid reporting requirements. We assessed the feasibility of co-ordinated real-time centralised pathology review (CPR), encompassing molecular diagnostics and contemporary genomics (RNA-seq/DNA methylation-array). This nationwide trial in medulloblastoma (80 UK diagnoses/year) introduced a national reference centre (NRC) and assessed its performance and reporting to W
Like
Comment
Share
